Payment overview · 2025
General Payments
$758.71
39 reported records · 12 companies
Healthcare provider profile · identity verified
Dana J Wright, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GERMANTOWN, TN · NPI 1801897053
Verified facts
What the public records show
CMS Open Payments records show Dana J Wright, MD received $758.71 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $251.91 | 33.2% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.85 | 11.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.83 | 10.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.05 | 9.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.77 | 8.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.61 | 6.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.84 | 6.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.46 | 4.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.99 | 4.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.10 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.83 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.47 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $758.71 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.34 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.28 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.85 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $84.85 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $77.83 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.05 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.77 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.61 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.54 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.46 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.46 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.46 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.99 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 33 |
| Losartan Potassium | Losartan Potassium | 115 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 38 |
| Lisinopril | Lisinopril | 109 | 31 |
| Omeprazole | Omeprazole | 105 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 30 |
| Potassium Chloride | Potassium Chloride | 94 | 24 |
| Furosemide | Furosemide | 92 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 31 |
| Metformin Hcl Er | Metformin Hcl | 72 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 38 |
| Carvedilol | Carvedilol | 66 | 24 |
| Spironolactone | Spironolactone | 65 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | suppressed |
| Gabapentin | Gabapentin | 59 | suppressed |
| Alprazolam | Alprazolam | 58 | suppressed |
| Ezetimibe | Ezetimibe | 57 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 56 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 13 |
| Meloxicam | Meloxicam | 52 | 18 |
| Famotidine | Famotidine | 51 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 17 |
| Methylprednisolone | Methylprednisolone | 48 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Allopurinol | Allopurinol | 47 | 15 |
| Metformin Hcl | Metformin Hcl | 46 | 12 |
| Simvastatin | Simvastatin | 44 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 13 |
| Ozempic | Semaglutide | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 26 |
| Atenolol | Atenolol | 34 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Eliquis | Apixaban | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 31 |
| Ramipril | Ramipril | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 23 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 13 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.71 · 39 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, COMIRNATY, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error